2.3.1.135	cellular retinol-binding protein	CRBP, required for enzyme activity, CRBP-I and CRBP-III each compensate for the absence of the other, specifically in mammary tissue, adipose tissue, muscle, and heart	674449	
2.3.1.135	cellular retinol-binding protein	i.e. CRALBP, in presence of palmitoyl-CoA and CRALBP, Muller cell membranes synthesize 11-cis-retinyl ester from 11-cis-retinol at a rate which is 20fold higher than that of all-trans-retinyl ester, in absence of CRALBP, 11-cis-retinyl ester synthesis is greatly reduced by 7fold	672075	
2.3.1.135	additional information	activation and mRNA expression for LRAT is blocked completely in vivo by actinomycin D	638614, 638624	
2.3.1.135	additional information	activation is blocked completely in vivo by cycloheximide	638614	
2.3.1.135	additional information	retinoic acid must be continuously present to maintain LRAT gene expression in the ON position	638624	
2.3.1.135	additional information	the pollutant 2,3,7,8-tetrachlorodibenzo-4-dioxin, i.e. TCDD, induces enzyme expression in the kidney, induction mechanism, the expression of the cellular retinol binding protein I is unaffected, TCDD alters the retinoid metabolism regulation, expression and activity of cytochrome P450 A1 increases retinoic acid levels in kidney and liver, and enhances enzyme expression in the kidney	658432	
2.3.1.135	N-(4-hydroxyphenyl)-retinamide	necessary dose, 0.5 mg	638616	
2.3.1.135	N-(4-hydroxyphenyl)-retinamide	restores normal level of LRAT activity in vitamin A depleted rats	638616	
2.3.1.135	retinoic acid	-	638619	
2.3.1.135	retinoic acid	minimal dose for significant increase in LRAT activity and mRNA expression: 0.005 mg	638624